Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21611380 | 0.88 | MAPT (0.35) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21611385 | 0.88 | MAPT (0.35) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL21611382 | 0.88 | MAPT (0.35) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17802901 | 0.83 | MAPT (0.36) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8647198 | 0.79 | MAPT (0.39) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19318890 | 0.79 | MAPT (0.39) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17008342 | 0.79 | MAPT (0.33) | MAPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9729278 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C9CYP2C19PPM1B | |
| SCHEMBL12156499 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C9CYP2C19PPM1B | |
| SCHEMBL9728986 | 0.78 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP2C9CYP2C19PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112133-A1 | DIHYDRO PYRROLOQUINOLINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112133-A1 | DIHYDRO PYRROLOQUINOLINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112133-A1 | DIHYDRO PYRROLOQUINOLINE DERIVATIVES | HRH4, HRH2, BDKRB2 | MAPT 4877/4885CYP3A4 1093/4885CYP2D6 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.